Navigation Links
Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 - October 28, 2008.

More information on the poster session at ICAAC:

Sunday, October 26, 12:15 - 1:15 pm EST

Session 126; New Treatment Options in Skin and Soft Tissue Infections

Location: Hall C

Poster: L1515B

-- Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in

Complicated Skin and Skin Structure Infections Following IV and

Oral Step-down Therapy.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, amadacycline, formerly PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of amadacycline were compared to Zyvox (R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSI). In addition to amadacycline, Paratek is also developing other broad- and narrow-spectrum tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing nonantibacterial compounds with improved activity in serious inflammatory and neurodegenerative diseases. In addition, Paratek is encouraged by early evidence of the ability of tetracycline derivatives to affect mRNA splicing, as in SMA, which may also have activity in related orphan genetic disorders, such as cystic fibrosis (CF) and Duchene Muscular Dystrophy.

Paratek has active collaborations with Merck & Co., MerckSerono, Warner-Chilcott and FSMA to develop tetracycline-derived small molecule drugs for broad-spectrum use in treating community-acquired bacterial infections, multiple sclerosis (MS), acne & rosacea, and spinal muscular atrophy (SMA), respectively. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.


'/>"/>
SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
2. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
7. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
10. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
11. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... EU5 Magnetic Resonance Imaging (MRI) Systems Market Outlook to 2022 ... ... Outlook to 2022", provides key market data on the EU5 Magnetic ... of US dollars, volume (in units) and average prices (USD) within ... The report also provides company shares and distribution shares ...
(Date:2/20/2017)... 2017 Taiwan Biophotonic Co. (tBPC), a medical ... signs sensing solutions, today announced the CE Marking and ... oximeter, the oCare TM Pro 100, which is a ... devices space.  tBPC,s Wrist Pulse Oximeter, the ... and reliable method to measure and record heart rate ...
(Date:2/20/2017)... TEMPE, Ariz. , Feb. 20, 2017 /PRNewswire/ ... to the medical device industry, announced today that ... Vention Medical,s Device Manufacturing Services business.  ... bolsters its position as a leading services provider ... MedPlast,s acquisition will further expand the company,s ...
Breaking Medicine Technology:
(Date:2/20/2017)... ALEXANDRIA, VA (PRWEB) , ... February 20, 2017 , ... ... with Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, ... of 2018 on a site just outside of Old Town. , The three-story ...
(Date:2/20/2017)... ... 2017 , ... Researchers at the University of Pittsburgh School of Medicine have ... may predict response to a particular class of drugs, not just in patients with ... new findings were published in Proceedings of the National Academy of Science. , “These ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Biscom , the ... the first IoT device from Biscom designed to deliver confidential patient information securely ... at HIMSS17 and will be conducting demonstrations at Booth #374. ...
(Date:2/20/2017)... ... ... a Population Health Software Company, is pleased to announce a move to a larger office ... the size of the previous location while bringing life back to a medical practice building ... are excited to expand our footprint to better serve our growing client base. We ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and Center ... a joint event at Chuck E. Cheese’s locations throughout New England, New York and ... the opportunity to experience the fun of visiting Chuck E. Cheese’s in a sensory-friendly ...
Breaking Medicine News(10 mins):